Accessibility to targeted oncology drugs in Slovenia and selected European countries
Abstract Aim The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2008-02, Vol.44 (3), p.408-418 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 3 |
| container_start_page | 408 |
| container_title | European journal of cancer (1990) |
| container_volume | 44 |
| creator | Kos, Mitja Obradovic, Marko Mrhar, Ales |
| description | Abstract Aim The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries. |
| doi_str_mv | 10.1016/j.ejca.2007.11.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70274240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804907009641</els_id><sourcerecordid>70274240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-ff3bdfb5ca8a78633269e3c740d7bc7b9158ee06f80d1dcb7064d020b6343de03</originalsourceid><addsrcrecordid>eNp9kU1r3DAQhkVoabbb_oEcii_tzc7Ili0JSiGEtA0Eekh6FrI0XuR6pa1kB_bfR2aXFnroaS7POx_PEHJFoaJAu-uxwtHoqgbgFaUV1HBBNlRwWYJo61dkA7KVpQAmL8nblEbIoGDwhlxSQdtWAmzI040xmJLr3eTmYzGHYtZxhzPaIngTprA7FjYuu1Q4XzxO4Rm904X2tkg4oVm5uyWGA2pfmLD4OTpM78jrQU8J35_rlvz8evd0-718-PHt_vbmoTSskXM5DE1vh741WmguuqapO4mN4Qws7w3vJW0FInSDAEut6Tl0zOYr-65hjUVotuTTqe8hht8LplntXTI4TdpjWJLiUHNWsxWsT6CJIaWIgzpEt9fxqCio1aUa1epSrS4VpSpPyaEP5-5Lv0f7N3KWl4GPZ0Ano6cham9c-sPVQBmIvOqWfD5xmF08O4wqGYfeoHUxK1Q2uP_v8eWfuJmcd3niLzxiGsMSfbasqEq1AvW4fn19OnAA2THavAAP1qe2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70274240</pqid></control><display><type>article</type><title>Accessibility to targeted oncology drugs in Slovenia and selected European countries</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kos, Mitja ; Obradovic, Marko ; Mrhar, Ales</creator><creatorcontrib>Kos, Mitja ; Obradovic, Marko ; Mrhar, Ales</creatorcontrib><description>Abstract Aim The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2007.11.020</identifier><identifier>PMID: 18155900</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Accessibility ; Alemtuzumab ; Antibodies, Monoclonal - economics ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Antibodies, Neoplasm - economics ; Antibodies, Neoplasm - therapeutic use ; Antineoplastic Agents - economics ; Antineoplastic Agents - supply & distribution ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cancer ; Comparison ; Europe ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Medical sciences ; Neoplasms - drug therapy ; Neoplasms - economics ; Oncology ; Pharmacoepidemiology - methods ; Pharmacology. Drug treatments ; Rituximab ; Slovenia ; Targeted oncology drugs ; Trastuzumab ; Tumors</subject><ispartof>European journal of cancer (1990), 2008-02, Vol.44 (3), p.408-418</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-ff3bdfb5ca8a78633269e3c740d7bc7b9158ee06f80d1dcb7064d020b6343de03</citedby><cites>FETCH-LOGICAL-c439t-ff3bdfb5ca8a78633269e3c740d7bc7b9158ee06f80d1dcb7064d020b6343de03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804907009641$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20140834$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18155900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kos, Mitja</creatorcontrib><creatorcontrib>Obradovic, Marko</creatorcontrib><creatorcontrib>Mrhar, Ales</creatorcontrib><title>Accessibility to targeted oncology drugs in Slovenia and selected European countries</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Aim The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.</description><subject>Accessibility</subject><subject>Alemtuzumab</subject><subject>Antibodies, Monoclonal - economics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antibodies, Neoplasm - economics</subject><subject>Antibodies, Neoplasm - therapeutic use</subject><subject>Antineoplastic Agents - economics</subject><subject>Antineoplastic Agents - supply & distribution</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Comparison</subject><subject>Europe</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - economics</subject><subject>Oncology</subject><subject>Pharmacoepidemiology - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Rituximab</subject><subject>Slovenia</subject><subject>Targeted oncology drugs</subject><subject>Trastuzumab</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1r3DAQhkVoabbb_oEcii_tzc7Ili0JSiGEtA0Eekh6FrI0XuR6pa1kB_bfR2aXFnroaS7POx_PEHJFoaJAu-uxwtHoqgbgFaUV1HBBNlRwWYJo61dkA7KVpQAmL8nblEbIoGDwhlxSQdtWAmzI040xmJLr3eTmYzGHYtZxhzPaIngTprA7FjYuu1Q4XzxO4Rm904X2tkg4oVm5uyWGA2pfmLD4OTpM78jrQU8J35_rlvz8evd0-718-PHt_vbmoTSskXM5DE1vh741WmguuqapO4mN4Qws7w3vJW0FInSDAEut6Tl0zOYr-65hjUVotuTTqe8hht8LplntXTI4TdpjWJLiUHNWsxWsT6CJIaWIgzpEt9fxqCio1aUa1epSrS4VpSpPyaEP5-5Lv0f7N3KWl4GPZ0Ano6cham9c-sPVQBmIvOqWfD5xmF08O4wqGYfeoHUxK1Q2uP_v8eWfuJmcd3niLzxiGsMSfbasqEq1AvW4fn19OnAA2THavAAP1qe2</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Kos, Mitja</creator><creator>Obradovic, Marko</creator><creator>Mrhar, Ales</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Accessibility to targeted oncology drugs in Slovenia and selected European countries</title><author>Kos, Mitja ; Obradovic, Marko ; Mrhar, Ales</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-ff3bdfb5ca8a78633269e3c740d7bc7b9158ee06f80d1dcb7064d020b6343de03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Accessibility</topic><topic>Alemtuzumab</topic><topic>Antibodies, Monoclonal - economics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antibodies, Neoplasm - economics</topic><topic>Antibodies, Neoplasm - therapeutic use</topic><topic>Antineoplastic Agents - economics</topic><topic>Antineoplastic Agents - supply & distribution</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Comparison</topic><topic>Europe</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - economics</topic><topic>Oncology</topic><topic>Pharmacoepidemiology - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Rituximab</topic><topic>Slovenia</topic><topic>Targeted oncology drugs</topic><topic>Trastuzumab</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kos, Mitja</creatorcontrib><creatorcontrib>Obradovic, Marko</creatorcontrib><creatorcontrib>Mrhar, Ales</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kos, Mitja</au><au>Obradovic, Marko</au><au>Mrhar, Ales</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accessibility to targeted oncology drugs in Slovenia and selected European countries</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>44</volume><issue>3</issue><spage>408</spage><epage>418</epage><pages>408-418</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Aim The aim of the study is to compare the accessibility to targeted oncology drugs in Slovenia and selected European countries. Methods Accessibility of targeted oncology drugs was assessed by using their sales data, expressed in mg per individual dying of the cancer for which the drug was indicated. Results The time of introduction of targeted oncology drugs in Slovenia was in most cases similar to the comparison countries, except for alemtuzumab and rituximab. The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in other comparison countries. Ibritumomab had not been used in Slovenia until 2005, similar to France, Switzerland and UK. After 2003 the utilisation of trastuzumab in Slovenia started to rise substantially, approaching the average uptake in comparison countries. Conclusion The utilisation of targeted oncology drugs in Slovenia was in most cases lower than in comparison countries.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18155900</pmid><doi>10.1016/j.ejca.2007.11.020</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2008-02, Vol.44 (3), p.408-418 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70274240 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Accessibility Alemtuzumab Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived Antibodies, Neoplasm - economics Antibodies, Neoplasm - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - supply & distribution Antineoplastic Agents - therapeutic use Biological and medical sciences Cancer Comparison Europe Female Hematology, Oncology and Palliative Medicine Humans Male Medical sciences Neoplasms - drug therapy Neoplasms - economics Oncology Pharmacoepidemiology - methods Pharmacology. Drug treatments Rituximab Slovenia Targeted oncology drugs Trastuzumab Tumors |
| title | Accessibility to targeted oncology drugs in Slovenia and selected European countries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A50%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accessibility%20to%20targeted%20oncology%20drugs%20in%20Slovenia%20and%20selected%20European%20countries&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Kos,%20Mitja&rft.date=2008-02-01&rft.volume=44&rft.issue=3&rft.spage=408&rft.epage=418&rft.pages=408-418&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2007.11.020&rft_dat=%3Cproquest_cross%3E70274240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70274240&rft_id=info:pmid/18155900&rft_els_id=1_s2_0_S0959804907009641&rfr_iscdi=true |